Search results
Showing 1 to 15 of 41 results for anaphylaxis
Anaphylaxis: assessment and referral after emergency treatment (CG134)
This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
All NICE products on allergies and anaphylaxis. Includes any guidance, advice and quality standards.
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- About this quality standard
following emergency treatment for anaphylaxis:- For how long should a person who has received emergency treatment for...
For how long should a person who has received emergency treatment for anaphylaxis be observed?
For how long should a person who has received emergency treatment for anaphylaxis be observed? Any explanatory notes(if applicable) Why...
What is the annual incidence of anaphylaxis and its related outcomes within the UK?
Recommendation ID CG134/4 Question What is the annual incidence of anaphylaxis and its related outcomes within the UK? Any explanatory...
biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable) Why this is...
other chemical inflammatory mediators offer potential as indicators of anaphylaxis? Any explanatory notes(if applicable) Why this is...
other chemical inflammatory mediators offer potential as indicators of anaphylaxis? Any explanatory notes(if applicable) Why this is...
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable) Why this is...
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
anaphylactic reactions and related outcomes:- What is the annual incidence of anaphylaxis and its related outcomes within the UK? Any...